儿童哮喘胃酸反流治疗研究-猫眼课题宝

儿童哮喘胃酸反流治疗研究

批准号：

7474765

负责人：

Janet T. Holbrook

金额：

$45.77万

依托单位：

JOHNS HOPKINS UNIVERSITY

依托单位国家：

美国

项目类别：

财政年份：

2006

资助国家：

美国

项目状态：

已结题

起止时间：

2006-09-20 至 2011-06-30

来源：

https://reporter.nih.gov/project-details/7474765

关键词：

Acids Adrenal Cortex Hormones Adverse event Age-Years Agonist Asthma Breathing Bronchial Spasm CYP2C19 gene Child Clinical Clinical Trials Data Monitoring Committees Communication Cytochrome P450 Data Data Analyses Data Collection Data Coordinating Center Disease Documentation Dose Electronics Esophageal Frequencies Gastric Acid Gastroesophageal reflux disease Genetic Polymorphism Grant Healthcare Hour Inflammatory Informed Consent Interleukin-1 beta Interview Label Lansoprazole Lead Leadership Manuals Masks Measures Monitor Online Systems Operative Surgical Procedures Outcome Measure Participant Pathway interactions Patients Performance Pharmaceutical Preparations Placebos Plasma Procedures Production Protocols documentation Proton Pump Inhibitors Publications Random Allocation Randomized Randomized Clinical Trials Reflux Reporting Research Ethics Committees Research Infrastructure Research Personnel Respiratory physiology Score Severities Site Subgroup Symptoms System Testing Training Variant airway inflammation base cytokine data management design diaries follow-up knowledge base quality assurance response symposium web based interface

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): Gastroesophageal reflux (GER) is frequent in children with asthma, can induce bronchospasm, and increase airways reactivity. Children with asthma are often treated for GER with drugs to suppress gastric acid production. However, this treatment is expensive, and with unproven benefit. The primary objective in this proposal is to conduct a multi-site, randomized, clinical trial to test the hypothesis that treatment of GER with lansoprazole, an approved proton pump inhibitor, will decrease the frequency of exacerbations in children with poorly controlled asthma. The study will include 300 asthmatic children treated with inhaled corticosteroids, 6-16 years of age, with poor control defined by frequent symptoms, excessive beta agonist use, or frequent exacerbations. Participants will be randomly assigned to treatment with either lansoprazole or placebo for six months. The presence, severity, and relationship of GER to asthma symptoms will be determined with 24 hour esophageal pH monitoring, but randomization to treatment will not be influenced by the presences or severity of GER. The primary outcome measure is the proportion of participants who have exacerbations of asthma defined by diaries and interviews. Secondary outcome measures include asthma symptom and control scores, GER symptoms, lung function, and unscheduled health care contacts. Pre-defined subgroup analyses will examine the relationship between specific clinical features and the response to lansoprazole. Treatment response will also be evaluated with 3-hour post-dose plasma lansoprazole concentrations, and related to polymorphisms in CYP2C19, the cytochrome P450 pathway, and IL-1 beta, a pro-inflammatory cytokine. Tertiary studies will determine how the magnitude of GER impacts airways inflammation, as measured by the concentrations of H+ (pH) and NO in expired breath. The results of this trial should have a major impact on the understanding and treatment of GER in children with asthma.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文